Cancer is regarded as one of the leading causes of death worldwide, despite the progress of traditional therapies. Chemotherapy, radiotherapy, and surgery are often accompanied by significant side effects and the development of drug resistance contributes to making the fight against cancer even more challenging, which clearly highlights the urgent need to develop new therapeutic molecular approaches. In this context, natural peptides were introduced into the pharmaceutical market in the last decade and have replenished the ranks of effective anticancer agents due to their structural diversity, biocompatibility, and ability to selectively target tumor cells. Natural peptides play a dual role, directly inhibiting tumor growth and proliferation by inhibiting angiogenesis and, conversely, exhibiting an immunomodulatory effect by enhancing the activation of T lymphocytes and natural killer cells and positively altering the tumor microenvironment (TME). The aim of this work is to critically evaluate the available literature on the anticancer and immunomodulatory activities of natural peptides and their potential use, both as monotherapy and in combination therapy, with particular attention given to issues of stability, bioavailability, and scalability of production. As highlighted throughout this review, a promising area is the integration of natural peptides with their synthetic derivatives and combining them with modern approaches such as nanotechnology and personalized medicine, which opens new avenues in cancer treatment.
Tsaturyan et al. (Thu,) studied this question.